Literature DB >> 8418041

Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.

A F Verheul1, J A Van Gaans, E J Wiertz, H Snippe, J Verhoef, J T Poolman.   

Abstract

Meningococcal lipopolysaccharide (LPS)-derived oligosaccharides (OS) were coupled to tetanus toxoid (TT) and purified P1.7,16 outer membrane proteins (OMP). The immunogenicities of the conjugates with and without the addition of the adjuvant Quil A or the nonionic block polymer L121 were studied in mice. Immunotype L2 and L3,7,9 OS-TT conjugates induced immunoglobulin G (IgG) responses that were strongly augmented by Quil A and L121. These adjuvants not only enhanced the amount of IgG evoked but also shifted the IgG subclass distribution from mainly IgG1 toward the complement-activating subclasses IgG2a and IgG2b. The antibodies induced were directed against the OS part of meningococcal LPS. They were not bactericidal for group B meningococci. Both the L3,7,9 OS-P1.7,16 OMP conjugate and purified P1.7,16 OMP evoked a strong IgG response against the P1.7,16 OMP but not against the L3,7,9 LPS. These anti-OMP IgG responses were comparable to the IgG OMP-specific responses induced by the H44/76 or HIII-5 outer membrane vesicles but still did not lyse group B meningococcal strains. The IgG response evoked with OS-OMP or purified OMP consisted mainly of the IgG1 subclass, whereas the H44/76 or HIII-5 outer membrane vesicles induced high amounts of bactericidal IgG2a and IgG2b antibodies next to the IgG1 antibodies. The addition of the adjuvant Quil A or L121 to OS-OMP or OMP resulted in the induction of high levels of bactericidal anti-P1.7,16-specific OMP antibodies, as reflected by the presence of substantial amounts of IgG2a and IgG2b antibodies. These results indicate that (i) mouse anti-LPS antibodies evoked by LPS-derived OS-protein conjugates are not bactericidal for group B meningococci, (ii) extensive purification of P1.7,16 OMP can lead to the loss of the intrinsic adjuvant properties of outer membrane vesicle preparations, and (iii) the addition of suitable adjuvants restores the ability of these purified P1.7,16 OMP to induce bactericidal antibodies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418041      PMCID: PMC302704          DOI: 10.1128/iai.61.1.187-196.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

Review 1.  Polysaccharides and membrane vaccines.

Authors:  J T Poolman
Journal:  Adv Biotechnol Processes       Date:  1990

2.  Isolation of Neisseria meningitidis mutants deficient in class 1 (porA) and class 3 (porB) outer membrane proteins.

Authors:  J Tommassen; P Vermeij; M Struyvé; R Benz; J T Poolman
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

3.  Nonionic block polymer surfactants enhance the avidity of antibodies in polyclonal antisera against Streptococcus pneumoniae type 3 in normal and Xid mice.

Authors:  G J Van Dam; A F Verheul; G J Zigterman; M J De Reuver; H Snippe
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

4.  Structure of the L5 lipopolysaccharide core oligosaccharides of Neisseria meningitidis.

Authors:  F Michon; M Beurret; A Gamian; J R Brisson; H J Jennings
Journal:  J Biol Chem       Date:  1990-05-05       Impact factor: 5.157

5.  Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies.

Authors:  J S Kenney; B W Hughes; M P Masada; A C Allison
Journal:  J Immunol Methods       Date:  1989-07-26       Impact factor: 2.303

6.  Regulation of isotype immunoglobulin production by adjuvants in vivo.

Authors:  E E Karagouni; L Hadjipetrou-Kourounakis
Journal:  Scand J Immunol       Date:  1990-06       Impact factor: 3.487

7.  Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine.

Authors:  J J Donnelly; R R Deck; M A Liu
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

8.  Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay.

Authors:  K Saukkonen; M Leinonen; H Abdillahi; J T Poolman
Journal:  Vaccine       Date:  1989-08       Impact factor: 3.641

9.  Nonionic block polymer surfactants modulate the humoral immune response against Streptococcus pneumoniae-derived hexasaccharide-protein conjugates.

Authors:  G J Zigterman; K Schotanus; E B Ernste; G J Van Dam; M Jansze; H Snippe; J M Willers
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

10.  Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates.

Authors:  A F Verheul; A K Braat; J M Leenhouts; P Hoogerhout; J T Poolman; H Snippe; J Verhoef
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

View more
  13 in total

1.  Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines.

Authors:  W D Zollinger; E E Moran; S J Devi; C E Frasch
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

2.  Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens.

Authors:  Jerry C Nagaputra; Christine S Rollier; Manish Sadarangani; J Claire Hoe; Ojas Hrakesh Mehta; Gunnstein Norheim; Muhammad Saleem; Hannah Chan; Jeremy P Derrick; Ian Feavers; Andrew J Pollard; E Richard Moxon
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

3.  Characterization of an antigenic oligosaccharide from Leptospira interrogans serovar pomona and its role in immunity.

Authors:  A Midwinter; T Vinh; S Faine; B Adler
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

4.  Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response.

Authors:  L Steeghs; B Kuipers; H J Hamstra; G Kersten; L van Alphen; P van der Ley
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

5.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

6.  Th1 and Th2 cell involvement in immune response to Salmonella typhimurium porins.

Authors:  M Galdiero; L De Martino; A Marcatili; I Nuzzo; M Vitiello; G Cipollaro de l'Ero
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

Review 7.  Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.

Authors:  A F Verheul; H Snippe; J T Poolman
Journal:  Microbiol Rev       Date:  1993-03

8.  Immunization with recombinant Sao protein confers protection against Streptococcus suis infection.

Authors:  Yuanyi Li; Marcelo Gottschalk; Miriam Esgleas; Sonia Lacouture; J Daniel Dubreuil; Philip Willson; Josee Harel
Journal:  Clin Vaccine Immunol       Date:  2007-06-13

9.  Development, characterization, and biological properties of meningococcal immunotype L3,7,(8),9-specific monoclonal antibodies.

Authors:  A F Verheul; A J Kuipers; A K Braat; H A Dekker; C C Peeters; H Snippe; J T Poolman
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

Review 10.  Current status of meningococcal group B vaccine candidates: capsular or noncapsular?

Authors:  J Diaz Romero; I M Outschoorn
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.